Japanese drugmaker Takeda announced its cancer medication Ninlaro will be subject to its 340B contract pharmacy policy.
News Alert
Takeda Becomes 29th Drugmaker to Implement 340B Contract Pharmacy Restrictions
Japanese pharmaceutical giant Takeda last Friday became the 29th drugmaker to place conditions on 340B pricing in the contract pharmacy [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.